Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Depreciation & Amortization (CF) (2016 - 2025)

CytomX Therapeutics' Depreciation & Amortization (CF) history spans 12 years, with the latest figure at $473000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 25.8% year-over-year to $473000.0; the TTM value through Dec 2025 reached $1.2 million, down 24.17%, while the annual FY2025 figure was $1.2 million, 24.17% down from the prior year.
  • Depreciation & Amortization (CF) reached $473000.0 in Q4 2025 per CTMX's latest filing, up from $98000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $643000.0 in Q3 2021 to a low of $98000.0 in Q3 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $486900.0, with a median of $516000.0 recorded in 2023.
  • The largest YoY upside for Depreciation & Amortization (CF) was 25.8% in 2025 against a maximum downside of 75.06% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $639000.0 in 2021, then decreased by 10.49% to $572000.0 in 2022, then fell by 21.5% to $449000.0 in 2023, then fell by 16.26% to $376000.0 in 2024, then rose by 25.8% to $473000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Depreciation & Amortization (CF) are $473000.0 (Q4 2025), $98000.0 (Q3 2025), and $310000.0 (Q2 2025).